Hoth Therapeutics (Hoth Therapeutics) Forward PE Ratio : 0.00 (As of May. 27, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Forward PE Ratio?

Hoth Therapeutics's Forward PE Ratio for today is 0.00.

Hoth Therapeutics's PE Ratio without NRI for today is 0.00.

Hoth Therapeutics's PE Ratio for today is 0.00.

Hoth Therapeutics Forward PE Ratio Historical Data

The historical data trend for Hoth Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics Forward PE Ratio Chart

Hoth Therapeutics Annual Data

Trend

Forward PE Ratio

Hoth Therapeutics Quarterly Data

Forward PE Ratio

Competitive Comparison of Hoth Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Hoth Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hoth Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's Forward PE Ratio falls into.

Hoth Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Hoth Therapeutics (NAS:HOTH) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Hoth Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023